Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, anticholinergic drugs can increase cognitive risk, and the evidence is substantial. Research involving over 1.5 million subjects across multiple studies shows that using anticholinergic medications for three months or longer raises the risk of dementia by approximately 46 percent. This finding has transformed how doctors think about medication safety in aging populations, revealing that some of the most commonly prescribed drugs—from bladder medications to certain antidepressants—carry cognitive consequences that were poorly understood until recent years. The risk is not theoretical or limited to extreme cases. A 68-year-old taking oxybutynin for overactive bladder, a 72-year-old on amitriptyline for depression, or a 75-year-old using diphenhydramine for sleep are all exposed to this cognitive risk.
What makes this particularly challenging is that these medications are prescribed for legitimate, often uncomfortable conditions. The cognitive cost isn’t inevitable or equally distributed, but it’s real enough that doctors and patients now need to weigh it carefully. Recent research from 2025 and 2026 continues to confirm and refine our understanding of this risk. A systematic review published in March 2025 examined the relationship between anticholinergic burden and dementia across multiple studies, while 2026 research specifically investigating overactive bladder medications found significant associations with dementia risk. Understanding which drugs matter most, who faces the highest risk, and what alternatives exist has become essential information for anyone managing their health or caring for an aging relative.
Table of Contents
- What Does the Research Evidence Show About Anticholinergic Drugs and Dementia Risk?
- Which Anticholinergic Medications Carry the Highest Cognitive Risk?
- How Does Exposure Duration and Dosage Affect Cognitive Risk?
- Should You Stop Taking These Medications or Adjust Them?
- Who Faces the Highest Risk From Anticholinergic Medications?
- Recent Research From 2025 and 2026: What Have We Learned?
- Moving Forward With Anticholinergic Medications and Brain Health
- Conclusion
What Does the Research Evidence Show About Anticholinergic Drugs and Dementia Risk?
The evidence linking anticholinergic medications to dementia comes from rigorous, large-scale research rather than anecdotal reports. A meta-analysis synthesizing data from 14 longitudinal and case-control studies examined outcomes in 1,564,181 subjects and found a consistent association between anticholinergic drug use and increased risk of both all-cause dementia and Alzheimer’s disease specifically. This wasn’t a marginal finding—the magnitude of increased risk was substantial enough to alter clinical practice guidelines in several countries. Critically, the research shows a dose-dependent relationship: both low and high anticholinergic burdens increase dementia risk, but higher exposures correlate with greater risk. This means it’s not simply a matter of using these drugs occasionally versus regularly—the longer someone takes them and the higher the doses, the more their cognitive risk rises.
The specific timeframe matters too. Using anticholinergic medications for three months or less appears to carry lower risk than use exceeding three months, suggesting that exposure duration accumulates effects in a measurable way. What distinguishes these findings is their consistency across different study types and populations. Longitudinal studies, which follow people over time and measure cognitive decline as it happens, show similar patterns to case-control studies that compare dementia patients with similar people who didn’t develop dementia. When different research methodologies arrive at the same answer using different populations and time periods, it strengthens confidence that the relationship is genuine rather than a statistical artifact.
Which Anticholinergic Medications Carry the Highest Cognitive Risk?
Not all anticholinergic drugs carry equal cognitive risk—some drug categories show much stronger associations with dementia than others. The highest-risk categories include antiparkinson medications (used for Parkinson’s disease), urological and bladder drugs like oxybutynin and tolterodine, certain antidepressants including amitriptyline and doxepin, antipsychotics, antiepileptic drugs, and first-generation antihistamines like diphenhydramine and chlorpheniramine. The presence of anticholinergic activity in depression medication matters; while newer antidepressants like SSRIs have minimal anticholinergic properties, older tricyclic antidepressants like amitriptyline carry significant anticholinergic burden. One important limitation in the research is that the highest-risk medications often treat conditions themselves associated with dementia risk. Depression, for example, is linked to cognitive decline, and older adults taking amitriptyline may have depression that independently contributes to their dementia risk.
Similarly, Parkinson’s disease itself can lead to cognitive problems. This creates a challenge in interpretation: does the medication increase dementia risk, or are patients with higher risk conditions more likely to receive these medications? Recent research has attempted to address this by controlling for underlying conditions, and the association between anticholinergic use and dementia remains significant even after accounting for these factors. Interestingly, not all anticholinergic drugs in the research show increased dementia risk. Cardiovascular medications with anticholinergic properties and gastrointestinal drugs don’t show the same cognitive associations. This suggests that the location of drug activity in the body, the specific mechanism of action, or which anticholinergic receptors are affected in the brain versus periphery may matter. It’s a reminder that “anticholinergic” is a broad chemical classification, and not all drugs in that category affect cognition equally.
How Does Exposure Duration and Dosage Affect Cognitive Risk?
The relationship between how much anticholinergic medication someone takes and for how long is far from proportional—small increases in exposure can translate to meaningful changes in cognitive risk. A person taking a standard dose of oxybutynin for overactive bladder for one month faces lower risk than someone taking the same medication for two years. The duration effect suggests that anticholinergic drugs may produce cumulative damage to cognitive tissue, with each month of exposure adding to the total burden. This dose-dependent pattern creates practical challenges for prescribing. A lower dose of a risky medication might carry minimal risk, but it also might not adequately treat the underlying condition. A doctor prescribing 5 mg of oxybutynin daily might reduce the cognitive risk compared to 10 mg, but if the lower dose leaves the patient with uncontrolled bladder urgency that severely impacts quality of life, the practical choice becomes murky.
The cognitive risk isn’t large enough at lower doses to make the decision obvious, yet it’s present enough to require discussion and monitoring. For someone taking such a medication for decades, the cumulative cognitive impact becomes concerning. Recent 2026 research on overactive bladder medications has been particularly useful in clarifying this dose-response relationship. Patients who used bladder anticholinergics intermittently showed lower dementia associations than those with continuous use. Some patients need these medications during seasons of high urinary urgency but not year-round; this pattern of intermittent use may offer a way to treat the underlying condition while limiting cognitive exposure. However, this distinction isn’t always possible—many patients need consistent medication management—and it highlights why individualized decision-making with a doctor becomes essential rather than applying a one-size-fits-all rule.
Should You Stop Taking These Medications or Adjust Them?
The answer is not a simple yes or no—stopping an anticholinergic medication that’s effectively treating an urgent problem creates its own set of problems. A patient whose overactive bladder was making her afraid to leave the house or engage socially shouldn’t simply stop oxybutynin based on dementia risk statistics. Conversely, someone taking diphenhydramine nightly for sleep should explore alternatives, since antihistamines are neither particularly effective for long-term sleep nor necessary for medical reasons the way treatments for depression or Parkinson’s disease are. The practical approach involves honest conversation with a doctor about whether the condition the medication treats is worth its cognitive cost. Several strategies can reduce anticholinergic exposure without abandoning necessary treatment. First, doctors can review whether the medication is still necessary—patients sometimes continue drugs prescribed years ago that are no longer addressing an active problem. Second, dose reduction is often possible, particularly if slightly lower efficacy is acceptable. Third, there are frequently alternatives with less or no anticholinergic activity.
Someone on amitriptyline for depression might switch to an SSRI like sertraline with minimal cognitive burden. Someone on diphenhydramine for sleep might explore melatonin or sleep hygiene changes. Someone on oxybutynin for bladder urgency might try mirabegron, a different class of drug with less anticholinergic activity. These switches aren’t always possible—some patients don’t tolerate alternatives—but they should be considered. The tradeoff becomes most difficult in conditions like Parkinson’s disease, where anticholinergic medications sometimes provide symptom relief that other drugs don’t, or in severe depression where amitriptyline might be uniquely effective for an individual. In these cases, the cognitive risk doesn’t disappear, but it becomes one factor among many rather than a reason to automatically stop treatment. Older adults living with Parkinson’s tremor or severe depression deserve effective treatment, even if that treatment carries cognitive risk. What changes is that everyone involved—patient, family, and doctor—should be aware of the risk and should monitor cognitive function more carefully, looking for signs that the medication is contributing to decline.
Who Faces the Highest Risk From Anticholinergic Medications?
Age matters significantly. Middle-aged and older adults, particularly those 55 and older, are most vulnerable to anticholinergic-related cognitive decline. The aging brain itself undergoes changes that may make it more sensitive to these drugs—brain plasticity decreases, cognitive reserve diminishes, and the blood-brain barrier may handle medications differently. A 45-year-old taking oxybutynin faces less risk than a 75-year-old taking the identical medication, all else equal. Beyond age, someone already showing signs of cognitive impairment or carrying genetic risk factors for dementia (such as the APOE4 gene variant) may face amplified risk from anticholinergic exposure. One significant limitation in the current research is that it hasn’t fully clarified which individuals tolerate anticholinergic exposure without apparent cognitive impact and which experience accelerated decline.
Some people take these medications for years without detectable cognitive harm, while others show rapid mental deterioration. Genetic factors, brain structure, underlying neurodegenerative processes that haven’t yet caused symptoms, and other medications all likely play roles in this variability. For now, the safest approach is to assume anyone 55 or older faces meaningful risk from prolonged anticholinergic exposure, but acknowledge that individual responses vary and monitoring is essential. Patients with existing dementia or mild cognitive impairment face accelerated decline when exposed to anticholinergic medications. Rather than a gradual process, cognitive loss can quicken. This observation has led to warnings in clinical guidelines that anticholinergic medications should be particularly avoided in people who already have diagnosed cognitive impairment. For someone showing early signs of memory loss or cognitive decline, continuation of an anticholinergic medication carries high stakes that warrant stronger consideration of discontinuation or switching to alternatives.
Recent Research From 2025 and 2026: What Have We Learned?
The latest research has added important nuance to our understanding of anticholinergic risk. A systematic review published in March 2025 confirmed what earlier research suggested: anticholinergic burden is consistently associated with increased dementia risk. But importantly, this 2025 review also examined anticholinergic exposure in people who already have dementia and found that these medications can accelerate cognitive decline even in those with established disease. This distinction matters—the risk isn’t just about developing dementia; it’s also about worsening existing cognitive problems in patients who are already vulnerable.
Complementing the pharmacological research, 2025 stem cell-based studies have begun exploring the biological mechanisms underlying anticholinergic cognitive damage. These laboratory studies show how anticholinergic activity affects neural cells in ways that could explain why population studies find increased dementia risk. Understanding the mechanism—how the drugs actually harm brain cells—provides confidence that the association found in large human studies reflects genuine causation rather than coincidence. Meanwhile, 2026 research has specifically investigated overactive bladder medications, one of the most commonly prescribed anticholinergic categories. That research found significant associations between bladder anticholinergic use and dementia risk in a large prevalent-user cohort, making the connection harder to dismiss as coincidence or confounding by indication.
Moving Forward With Anticholinergic Medications and Brain Health
The future of managing anticholinergic risk likely involves several parallel approaches. Drug development is moving toward less anticholinergic alternatives for conditions that currently require anticholinergic medications—mirabegron for bladder problems, newer antihistamines for allergies, and SSRIs for depression represent progress in this direction. As these alternatives improve, the clinical case for anticholinergic drugs weakens. Second, better tools for measuring individual anticholinergic burden are being developed and refined.
Rather than simply counting medications, doctors increasingly use anticholinergic scales that account for dose and potency, which should help identify patients at highest risk and prioritize interventions for them. Third, the conversation about cognitive health in aging is changing to incorporate medication review as a standard practice. Dementia prevention strategies now commonly include a review of medications, particularly in middle-aged adults. If someone is on an anticholinergic medication, the question “Is this still necessary?” becomes as important as “Is this medication controlling my symptoms?” This represents a maturation of dementia prevention thinking—not as something limited to omega-3 supplements or cognitive exercises, but as something that necessarily involves careful medication management and risk-benefit analysis.
Conclusion
Anticholinergic drugs do increase cognitive risk, confirmed by large-scale research, multiple recent studies, and a dose-dependent relationship between exposure and dementia risk. The effect is substantial enough to matter—a 46 percent increase in dementia risk with exposure of three months or longer—and applies to widely used medications including bladder drugs, certain antidepressants, antihistamines, and others. However, this risk must always be weighed against the genuine benefits these medications provide for people suffering from the conditions they treat.
The path forward involves three-way conversations between patients, families, and doctors about whether specific anticholinergic medications are still necessary, whether lower doses might suffice, and whether alternatives with less cognitive burden exist. For many people, especially those over 55, continuing an anticholinergic medication should include regular cognitive monitoring to catch any acceleration of decline. The research is clear: cognitive risk is real and measurable. The clinical response should be equally clear: thoughtful, individualized decision-making that doesn’t ignore this risk but also doesn’t overreact to it.
You Might Also Like
- Why Moving Can Be Hard for People With Cognitive Decline
- Can Medication Burden Increase Dementia-Like Symptoms?
- Can Fast Food Habits Influence Cognitive Aging?
Related reading
- why Medication Reviews Matter After Age 65
- how Pharmacists Can Help Protect Brain Health
- can Sleep Aids Worsen Dementia Symptoms
- why Some Allergy Medicines Affect Memory
- how to Talk to a Doctor About Cognitive Side Effects
For more on this topic, see NIH MedlinePlus — cognitive testing.
